Tracers / [161Tb]Tb-PSMA-I&T
[161Tb]Tb-PSMA-I&T
Also written as PSMA I&T; PSMA-I&T; [Tb-161]Tb-PSMA-I&T
- Radionuclide
- Tb-161 t½ 9907.2 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
What it is
- Compound class
- —
- Target / mechanism
- —
- Clinical application
- —
- Theranostic pair
- <a href="/tracers/ga68-psma-it/">ga68-psma-it</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | approximately 99% | PSMA-1 | 42334711 2026 EJNMMI Radiopharm Chem via a Trasis MiniAiO synthesizer |
Need this precursor?We can point you to suppliers for [161Tb]Tb-PSMA-I&T, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68.